Editorial comment

Ascertaining the clinical benefit for lymph node dissection (LND) at the time of radical nephrectomy (RN) for renal cell carcinoma (RCC) has been challenging. At issue in determining the therapeutic or staging benefits of LND may be the quality of the lymph node dissection (number of lymph nodes harvested) or anatomic boundaries. Furthermore, prior studies have been limited by these issues and level of evidence. In this issue of Urology, Gershman et al. applied a validated observational analysis methodology with a large oncologic database to emulate 2 clinical trials in attempt to further examine the potential therapeutic benefit of LND at the time of RN for RCC.
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research